Private equity’s expansion into healthcare has generated substantial policy attention and inadequate empirical scrutiny. Price transparency data offers a partial remedy.
The investigative and regulatory challenge with PE-backed healthcare providers is timing. When a PE firm acquires a physician group—emergency medicine, anesthesia, and radiology have been the most targeted specialties—the rate implications of that acquisition do not appear in publicly available financial data for years. Hospital cost reports are annual and backward-looking. PE-backed entities are typically private, exempt from the SEC disclosure obligations that apply to public companies. State financial filings for healthcare entities vary in detail and timing.
Negotiated rates, however, are now public—for the hospital side of the transaction, at least. When a PE-backed physician group acquires exclusive contractual rights to provide services at a hospital (a common structure in emergency medicine and anesthesia), the hospital’s published rate files for those services begin to reflect the post-acquisition rates negotiated by the PE entity. The lag between acquisition and rate disclosure is a function of contract renewal cycles, but it is substantially shorter than the lag to financial statement disclosure.
MedPricer.org enables investigators to track rate changes in hospital-based services following identified PE acquisitions. The analysis requires knowing which hospitals have contracted with which PE-backed groups—information available from medical staff directories, CMS enrollment data, and industry databases—and then examining whether rates for affected service lines changed materially after the acquisition date.
This is not theoretical. Academic research has documented that PE acquisition of physician groups is associated with material rate increases in emergency medicine and anesthesia. The mechanism is the exclusive contract combined with the insurer’s inability to exclude the acquired group from its network without losing access to the hospital. MedPricer data makes it possible to identify the specific hospitals, the specific service lines, and the specific payers where this dynamic is most pronounced.
For journalists, the PE investigation frame enabled by MedPricer looks like this: identify a market where a major PE acquisition of a physician group has occurred; query MedPricer for the rates at affiliated hospitals for the affected service line, comparing pre- and post-acquisition periods where data allows; look for rate increases that exceed market trends; interview payer contract executives and hospital administrators about the negotiation dynamics. This is not a simple reporting task. But it is substantially more grounded than the alternative—relying on anonymous sources and industry-funded studies.
The regulatory application is similarly concrete. State attorneys general reviewing PE transactions in healthcare—as several have begun doing following high-profile bankruptcies and quality-of-care failures—can use MedPricer rate data as part of their investigative baseline. If a proposed acquisition involves a PE firm that has already acquired physician groups in other markets, the rate history in those prior markets is available and potentially probative of the likely effects in the target market.
The limitation is significant. MedPricer’s data covers hospital-based rates, not rates for free-standing physician offices or ambulatory surgery centers—settings where PE acquisition has also been extensive. Physician office rates are not currently subject to CMS transparency mandates. This is a substantial gap. The No Surprises Act’s arbitration data may eventually fill part of it, but that data is not yet systematically accessible.
The picture MedPricer provides is partial and requires corroboration. It is, nevertheless, orders of magnitude more informative than what was available before 2021—which was, essentially, nothing systematic.
